Beta
Trial Radar KI
Die klinische Studie NCT07498686 für RT-QuIC ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease 458 Biomarker-basiert Neuartig

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07498686 ist eine beobachtungsstudie zur Untersuchung von RT-QuIC und hat den Status offene rekrutierung. Die Studie startete am 1. Mai 2023 und soll 458 Teilnehmer aufnehmen. Durchgeführt von Xuanwu Hospital, Beijing ist der Abschluss für 23. Dezember 2026 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. März 2026 aktualisiert.
Kurzbeschreibung
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lewy neurites, neurons,...Mehr anzeigen
Offizieller Titel

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease

Erkrankungen
RT-QuIC
Weitere Studien-IDs
  • 115
NCT-Nummer
Studienbeginn (tatsächlich)
2023-05-01
Zuletzt aktualisiert
2026-03-27
Studienende (vorauss.)
2026-12-23
Geplante Rekrutierung
458
Studientyp
Beobachtungsstudie
Status
Offene Rekrutierung
Stichwörter
PD, MSA, PSP, Neurodegeneration disease, alpha-synuclein
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Control
Control: healthy subjects,
Nicht zutreffend
PD
parkinson's disease patients
Nicht zutreffend
MSA
MSA: multiple system atrophy
Nicht zutreffend
PSP
progressive supranuclear palsy
Nicht zutreffend
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
slope
slope of all Fluorescence value
From enrollment to the end of treatment at 21 weeks
MAX
Maximum fluorescence value
From enrollment to the end of treatment at 21 weeks
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
Akzeptiert gesunde Freiwillige
Ja

- Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn & Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.

  • Patients with Parkinson's syndrome but not primary PD, patients with brain surgery/deep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.
Xuanwu Hospital, Beijing logoXuanwu Hospital, Beijing
Zentrale Studienkontakte
Kontakt: Weiwei YANG, Ph.D., +86 010-83198271, [email protected]
2 Studienstandorte in 1 Ländern

Beijing Municipality

Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Abgeschlossen
Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Weiwei YANG, Kontakt, +86 010-83198271, [email protected]
Offene Rekrutierung